Table 4.

Comparison of CA FISH findings in this analysis with previously published findings for sputum cytology and sputum DNA methylation markers from this same cohort

Cases, n/N abnormalSensitivitySpecificityFully adjusted OR (95% CI)
All samples from previous reports and the current report
    Cytologic atypia*50/17429%83%1.8 (1.3-2.6)
    DNA methylation33/5264%64%6.5 (1.2-35.5)
        CA-FISH42/5576%88%29.9 (9.5-94.1)
Subset of samples on which all three biomarkers were performed
        Cytologic atypia20/4842%77%2.3 (0.8-6.4)
        DNA methylation33/4869%54%4.3 (1.0-19.8)
        CA-FISH37/4876%85%27.2 (7.8-94.1)
  • *From Ref. 15. Atypia is defined as moderate atypia or worse. OR is adjusted for age, sex, race/ethnicity, pack-years of smoking, smoking status at baseline, and year of enrollment into the cohort. Among controls, there were 400 of 2,347 (17%) who had ≥2 abnormal FISH markers for ≤18 mo proximal samples.

  • From Ref. 18. Methylation is defined as three or more of a panel of six markers methylated. OR is adjusted for age, sex, FEV1, pack-years of smoking, and current smoking status. Among controls there were 17 of 47 (36%) who had ≥2 abnormal FISH markers for ≤18 mo proximal samples.

  • Data from the current report. Positive FISH assay is defined as two or more of four FISH markers being abnormal. OR is adjusted for age, sex, FEV1, pack-years of smoking, and current smoking status. Among controls, there were 7 of 59 (12%) who had ≥2 abnormal FISH markers for ≤18 mo proximal samples.